Latest Elite Pharma Inc (ELTP) Headlines
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
GlobeNewswire - Wed Mar 05, 6:30AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200. The study results demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 42 subjects under fasted conditions and 38 subjects under fed conditions.
Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
GlobeNewswire - Tue Feb 18, 6:00AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study initiated in December 2013 for ELI-201, a twice-daily opioid abuse deterrent oxycodone product with abuse deterrent technology. Three different twice daily formulations developed by Elite were tested in the study. The study results demonstrate that all formulations in the study were bioequivalent to the reference drug based on pharmacokinetic measures including peak plasma concentration (Cmax) and area under the curve (AUC) for oxycodone blood plasma levels. The study was a single dose, open label, randomized, four period, four treatment, cross over study in 16 healthy volunteers under fasted conditions.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014
GlobeNewswire - Fri Feb 14, 8:49AM CST
Revenues Increase by 154%, Product Development Accelerating
Prolexic Publishes Infographic on Largest Attacks Mitigated in 2013
M2 - Fri Feb 14, 8:07AM CST
Prolexic Technologies, the global leader in Distributed Denial of Service (DDoS) protection services, today published a new infographic summarizing the statistics about the largest DDoS attacks it mitigated in each quarter of 2013.
Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014
GlobeNewswire - Mon Feb 10, 2:27PM CST
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today that management will host a conference call to provide a quarterly business update at 3:00 PM ET on Tuesday, February 18, 2014. Company executives will also conduct a question and answer session following their remarks.
Elite Pharmaceuticals Analyst Report offers Insight and Market Data by BrokerBank Securities, Inc.
PR Newswire - Mon Feb 10, 6:00AM CST
Elite Pharmaceuticals Inc. (OTCQB: ELTP) is a specialty pharmaceutical company that is principally engaged in the research, development, and the licensing of proprietary controlled-release drug delivery systems and products. Elite Pharmaceuticals was founded in 1984 and is headquartered in Northvale, New Jersey.
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product
GlobeNewswire - Tue Jan 14, 12:21PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for an undisclosed opioid abuse deterrent product utilizing Elite's proprietary pharmacological abuse deterrent technology.
Elite Pharmaceuticals Inc reports launch of pilot bioequivalence study of ELI-201 in alcohol & opioid dependence
M2 - Fri Dec 06, 10:00AM CST
Controlled release products company Elite Pharmaceuticals Inc (OTC BB:ELTP) reported on Thursday the start of dosing of a first pilot bioequivalence study in healthy volunteers for its twice daily abuse deterrent oxycodone/naltrexone product, ELI-201.
Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201
GlobeNewswire - Thu Dec 05, 11:50AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pilot bioequivalence study in healthy volunteers for ELI-201, the Company's twice daily abuse deterrent oxycodone/naltrexone product.
Elite Pharmaceuticals converts chairs' bridge loan to convertible note
M2 - Wed Nov 27, 5:47AM CST
Controlled release drug company Elite Pharmaceuticals Inc (OTC BB:ELTP) revealed on Tuesday the conversion of its chairman's bridge loan to an unsecured convertible note.
Elite Pharmaceuticals Announces Conversion of Treppel Bridge Loan to Convertible Note
GlobeNewswire - Tue Nov 26, 6:00AM CST
Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that Jerry Treppel, Elite's Chairman of the Board, has elected to convert the outstanding principal amount owed as part of the $1 million Treppel Credit Line to an unsecured convertible note ("Note"). The Treppel Credit Line remains in effect and is available, in full, through July 2014, the remaining term of the credit line.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2014
GlobeNewswire - Thu Nov 14, 3:23PM CST
Revenues Increase by 83%, Product Development Accelerating
Elite Pharmaceuticals, Inc. to Host Second Quarter Business Update Call on November 18, 2013
GlobeNewswire - Thu Nov 14, 6:45AM CST
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today that management will host a conference call to provide a quarterly business update at 3:00 PM ET on Monday, November 18, 2013. Company executives will also conduct a question and answer session following their remarks.
Elite Pharmaceuticals Inc signs up to USD1m credit line agreement with its president and CEO
M2 - Thu Oct 17, 6:08AM CDT
Controlled release drug company Elite Pharmaceuticals Inc (OTC BB:ELTP) reported on Wednesday the launch of a credit line agreement with its president and CEO, Nasrat Hakim.
Elite Pharmaceuticals Announces Bridge Loan Facility
GlobeNewswire - Wed Oct 16, 6:45AM CDT
Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that it has entered into a credit line agreement ("Credit Line") with Nasrat Hakim, Elite's President and Chief Executive Officer. Pursuant to this agreement, Mr. Hakim has agreed to provide to Elite a line of credit not to exceed $1,000,000. Proceeds will be used to support Elite's acceleration of product development activities.
Elite Pharmaceuticals Inc signs manufacturing and license agreement with Epic Pharma LLC for 12 generic products
M2 - Wed Oct 09, 11:26AM CDT
Drug products company Elite Pharmaceuticals Inc (OTC BB:ELTP) revealed on Tuesday the launch of a Manufacturing and License Agreement for 12 generic products.
Elite Pharmaceuticals Announces Manufacturing and License Agreement for Twelve Generic Products
GlobeNewswire - Tue Oct 08, 6:45AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the signing of a Manufacturing and License Agreement ("Agreement") with Epic Pharma, LLC ("Epic"). Pursuant to the Agreement, Epic will have the right to manufacture, market and sell in the United States and Puerto Rico twelve generic products owned by Elite. Of the twelve products, Epic will have the exclusive right to market six products and the non-exclusive right to market six additional products. Epic is also responsible for all regulatory and pharmacovigilance matters related to the products and for all costs related to the site transfer for all products. Pursuant to the Agreement, Elite will receive a license fee and milestone payments. The license fee will be computed as a percentage of the gross profit, as defined in the Agreement, and earned by Epic as a result of sales of the products. The license fee is payable monthly for the term of the Agreement. The first milestone payment is due on or before November 15, 2013. Subsequent milestone payments are due upon the filing of each product's supplement with the U.S. Food and Drug Administration ("FDA") and the FDA approval of site transfer for each product as specifically itemized in the agreement. The term of the License Agreement is 5 years and may be extended for an additional 5 years upon mutual agreement.
Elite Pharmaceuticals, Inc. Announces First Shipment of Generic Naltrexone Hydrochloride
GlobeNewswire - Wed Sep 18, 6:51AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the initial shipment of naltrexone hydrochloride 50 mg tablets under the License, Manufacturing and Supply Agreement with its sales and marketing partner, triggering a milestone payment. Elite's sales and marketing partner will distribute the product as part of a multi-product distribution agreement.
Elite Pharmaceuticals Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Tue Sep 03, 8:46AM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), today announced it will be featured as a presenting company at the 15 Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2014
GlobeNewswire - Wed Aug 14, 3:29PM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the first quarter of fiscal year 2014 ended June 30, 2013.
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
GlobeNewswire - Wed Mar 05, 6:30AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200. The study results demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 42 subjects under fasted conditions and 38 subjects under fed conditions.
Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
GlobeNewswire - Tue Feb 18, 6:00AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study initiated in December 2013 for ELI-201, a twice-daily opioid abuse deterrent oxycodone product with abuse deterrent technology. Three different twice daily formulations developed by Elite were tested in the study. The study results demonstrate that all formulations in the study were bioequivalent to the reference drug based on pharmacokinetic measures including peak plasma concentration (Cmax) and area under the curve (AUC) for oxycodone blood plasma levels. The study was a single dose, open label, randomized, four period, four treatment, cross over study in 16 healthy volunteers under fasted conditions.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014
GlobeNewswire - Fri Feb 14, 8:49AM CST
Revenues Increase by 154%, Product Development Accelerating
Prolexic Publishes Infographic on Largest Attacks Mitigated in 2013
M2 - Fri Feb 14, 8:07AM CST
Prolexic Technologies, the global leader in Distributed Denial of Service (DDoS) protection services, today published a new infographic summarizing the statistics about the largest DDoS attacks it mitigated in each quarter of 2013.
Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014
GlobeNewswire - Mon Feb 10, 2:27PM CST
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today that management will host a conference call to provide a quarterly business update at 3:00 PM ET on Tuesday, February 18, 2014. Company executives will also conduct a question and answer session following their remarks.
Elite Pharmaceuticals Analyst Report offers Insight and Market Data by BrokerBank Securities, Inc.
PR Newswire - Mon Feb 10, 6:00AM CST
Elite Pharmaceuticals Inc. (OTCQB: ELTP) is a specialty pharmaceutical company that is principally engaged in the research, development, and the licensing of proprietary controlled-release drug delivery systems and products. Elite Pharmaceuticals was founded in 1984 and is headquartered in Northvale, New Jersey.
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product
GlobeNewswire - Tue Jan 14, 12:21PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for an undisclosed opioid abuse deterrent product utilizing Elite's proprietary pharmacological abuse deterrent technology.
Elite Pharmaceuticals Inc reports launch of pilot bioequivalence study of ELI-201 in alcohol & opioid dependence
M2 - Fri Dec 06, 10:00AM CST
Controlled release products company Elite Pharmaceuticals Inc (OTC BB:ELTP) reported on Thursday the start of dosing of a first pilot bioequivalence study in healthy volunteers for its twice daily abuse deterrent oxycodone/naltrexone product, ELI-201.
Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201
GlobeNewswire - Thu Dec 05, 11:50AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pilot bioequivalence study in healthy volunteers for ELI-201, the Company's twice daily abuse deterrent oxycodone/naltrexone product.
Elite Pharmaceuticals converts chairs' bridge loan to convertible note
M2 - Wed Nov 27, 5:47AM CST
Controlled release drug company Elite Pharmaceuticals Inc (OTC BB:ELTP) revealed on Tuesday the conversion of its chairman's bridge loan to an unsecured convertible note.
Elite Pharmaceuticals Announces Conversion of Treppel Bridge Loan to Convertible Note
GlobeNewswire - Tue Nov 26, 6:00AM CST
Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that Jerry Treppel, Elite's Chairman of the Board, has elected to convert the outstanding principal amount owed as part of the $1 million Treppel Credit Line to an unsecured convertible note ("Note"). The Treppel Credit Line remains in effect and is available, in full, through July 2014, the remaining term of the credit line.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2014
GlobeNewswire - Thu Nov 14, 3:23PM CST
Revenues Increase by 83%, Product Development Accelerating
Elite Pharmaceuticals, Inc. to Host Second Quarter Business Update Call on November 18, 2013
GlobeNewswire - Thu Nov 14, 6:45AM CST
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today that management will host a conference call to provide a quarterly business update at 3:00 PM ET on Monday, November 18, 2013. Company executives will also conduct a question and answer session following their remarks.
Elite Pharmaceuticals Inc signs up to USD1m credit line agreement with its president and CEO
M2 - Thu Oct 17, 6:08AM CDT
Controlled release drug company Elite Pharmaceuticals Inc (OTC BB:ELTP) reported on Wednesday the launch of a credit line agreement with its president and CEO, Nasrat Hakim.
Elite Pharmaceuticals Announces Bridge Loan Facility
GlobeNewswire - Wed Oct 16, 6:45AM CDT
Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that it has entered into a credit line agreement ("Credit Line") with Nasrat Hakim, Elite's President and Chief Executive Officer. Pursuant to this agreement, Mr. Hakim has agreed to provide to Elite a line of credit not to exceed $1,000,000. Proceeds will be used to support Elite's acceleration of product development activities.
Elite Pharmaceuticals Inc signs manufacturing and license agreement with Epic Pharma LLC for 12 generic products
M2 - Wed Oct 09, 11:26AM CDT
Drug products company Elite Pharmaceuticals Inc (OTC BB:ELTP) revealed on Tuesday the launch of a Manufacturing and License Agreement for 12 generic products.
Elite Pharmaceuticals Announces Manufacturing and License Agreement for Twelve Generic Products
GlobeNewswire - Tue Oct 08, 6:45AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the signing of a Manufacturing and License Agreement ("Agreement") with Epic Pharma, LLC ("Epic"). Pursuant to the Agreement, Epic will have the right to manufacture, market and sell in the United States and Puerto Rico twelve generic products owned by Elite. Of the twelve products, Epic will have the exclusive right to market six products and the non-exclusive right to market six additional products. Epic is also responsible for all regulatory and pharmacovigilance matters related to the products and for all costs related to the site transfer for all products. Pursuant to the Agreement, Elite will receive a license fee and milestone payments. The license fee will be computed as a percentage of the gross profit, as defined in the Agreement, and earned by Epic as a result of sales of the products. The license fee is payable monthly for the term of the Agreement. The first milestone payment is due on or before November 15, 2013. Subsequent milestone payments are due upon the filing of each product's supplement with the U.S. Food and Drug Administration ("FDA") and the FDA approval of site transfer for each product as specifically itemized in the agreement. The term of the License Agreement is 5 years and may be extended for an additional 5 years upon mutual agreement.
Elite Pharmaceuticals, Inc. Announces First Shipment of Generic Naltrexone Hydrochloride
GlobeNewswire - Wed Sep 18, 6:51AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the initial shipment of naltrexone hydrochloride 50 mg tablets under the License, Manufacturing and Supply Agreement with its sales and marketing partner, triggering a milestone payment. Elite's sales and marketing partner will distribute the product as part of a multi-product distribution agreement.
Elite Pharmaceuticals Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Tue Sep 03, 8:46AM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), today announced it will be featured as a presenting company at the 15 Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2014
GlobeNewswire - Wed Aug 14, 3:29PM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the first quarter of fiscal year 2014 ended June 30, 2013.
